Comparing two drug combos for relapsed follicular or marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a new drug, odronextamab, combined with lenalidomide works better than the current standard, rituximab combined with lenalidomide, for people whose follicular or marginal zone lymphoma has come back or not responded to prior treatment. It aims to see which combo is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grade 1, 2, or 3a) or marginal zone lymphoma (any type).
- Your lymphoma has returned or not responded after at least one prior treatment that included a CD20 antibody (like rituximab).
- You have at least one measurable tumor on a CT or MRI scan.
- You are able to care for yourself (ECOG score 0-2).
- You must agree to follow pregnancy precautions, not donate blood during treatment, and not share your medication.
- You must not have active infections, other cancers (except certain treated early-stage ones), or significant medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
This trial tests if a new drug called odronextamab is safe and works as well as a common antibody (rituximab) plus chemotherapy for people with a type of slow-growing lymphoma that hasn't been treated yet. It's for adults with grade 1-3a follicular lymphoma that is bulky stage II or stage III/IV.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
This trial tests a new combination of targeted drugs (zanubrutinib, lenalidomide, and rituximab) against a standard two-drug combination for people with newly diagnosed follicular lymphoma who need treatment right away. It aims to see if the three-drug combo is more effective.
Hear when a new Relapsed/Refractory Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.